Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine/Naloxone Dose Effects on Opioid Seeking
NCT03015246Phase 2Completed
- Sponsor
- Wayne State University
- Start
- Dec 2016
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buprenorphine + naloxone in opioid use disorder (OUD) (8 arms), sponsored by Wayne State University. Primary endpoint: Opioid price-inelasticity (economic demand) at 7 weeks. Started Dec 2016; status: completed.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT03015246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03015246.